Health Care Down on Mixed Earnings β Health Care Roundup
Health-care stocks declined broadly following mixed earnings reports from major companies.
Humana shares rose despite lower first-quarter profit due to Medicare Advantage Star Rating headwinds for 2026.
GE HealthCare Technologies cut its annual profit outlook citing higher costs for memory chips, oil, and freight.
The Canadian government approved the first G7 generic version of Ozempic by Dr. Reddy's Laboratories.
Humana maintained its full-year earnings projection despite the quarter's headwinds.
Bullish Signals
- Humana shares rallied despite reporting lower first-quarter profit due to headwinds from lower Medicare Advantage Star Ratings for 2026.
- The company reiterated its earnings projection for the year, signaling management's confidence in maintaining its full-year outlook.
Risk Factors
- Humana shares rallied despite reporting lower first-quarter profit due to earnings headwinds from lower Medicare Advantage Star Ratings for 2026.
- GE HealthCare Technologies cut its profit outlook for the year because prices for memory chips, oil, and freight jumped during the recent quarter.
- The Canadian government authorized a generic version of Ozempic developed by Dr. Reddy's Laboratories, making it the first G7 country to approve a generic version of the massively popular GLP-1 diabetes treatment.
Full Analysis
Health care stocks declined following mixed earnings reports and external market pressures on April 29, 2026. Humana shares rallied despite reporting lower first-quarter profit due to headwinds from reduced Medicare Advantage Star Ratings for 2026, though the company maintained its annual earnings projection. Conversely, GE HealthCare Technologies fell after cutting its full-year profit outlook amid rising costs for memory chips, oil, and freight during the recent quarter.
The sector saw significant regulatory developments as the Canadian government authorized a generic version of Ozempic, developed by Dr. Reddy's Laboratories. This move marks a historic milestone, making Canada the first G7 country to approve a generic formulation of the massively popular GLP-1 diabetes treatment.